Theriva Biologics Inc (TOVX)

Überblick Nachrichten Preisverlauf Forum Prognose

Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten

TOVX Should I Buy - Intellectia AI

Why is Theriva stock gaining Monday? - MSN

Theriva Biologics (TOVX) Surges Over 26%: Key Levels to Watch After BreakoutCall Resistance - newsline.com

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention - TechStock²

Theriva Biologics reports survival data from VCN-01 cancer trial - Investing.com

Theriva Biologics highlights promising VCN-01 Phase 1 results - TipRanks

$Theriva Biologics (TOVX.US)$ - Moomoo

Theriva Biologics (NYSE American: TOVX) shares VCN-01 Phase 1 head and neck cancer data - Stock Titan

Small trial: virus-immunotherapy combo linked to longer survival in head and neck cancer - Stock Titan

TOVX Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOperating Margin Analysis - newsline.com

Theriva Biologics Faces Quorum Issue Delaying Warrant Vote - TipRanks

Theriva Biologics (NYSE: TOVX) fails quorum, delays 16.18M-warrant share vote - Stock Titan

MSN Money - MSN

Number of shareholders of Theriva Biologics, Inc. – AMEX:TOVX - TradingView

Theriva Biologics (TOVX) Slides 8% as Stock Tests Key Support at $0.27Dark Pool Sentiment - The Legal Advocate

Theriva Biologics (TOVX) Faces Pressure: Stock Slides 8% as Key Support Levels Are TestedLeveraged ETF Flow - The Legal Advocate

Theriva Biologics (TOVX) Slides 6.15% as Stock Approaches Key Support at $0.28Thematic ETF Flow - newsline.com

Theriva Biologics (TOVX) Advances 4.99% as Stock Approaches Key Resistance at $0.33McClellan Oscillator - newsline.com

Theriva Biologics (TOVX) Gains Nearly 5% as Stock Attempts to Recover Key Support LevelsAI Trade Signals - The Legal Advocate

Theriva Biologics (TOVX) Slides 5.73% as Price Nears Critical Support at $0.28BPI Reversal - The Legal Advocate

Theriva Biologics (TOVX) Q1 2026 Earnings: Slight EPS Beat Boosts Sentiment for Clinical-Stage BiotechMargin Guidance - The Legal Advocate

Theriva Biologics (TOVX) Q1 2026 Earnings: Narrowed Loss Beats Expectations as Stock RisesBanking Earnings Report - Newser

Theriva Biologics (TOVX) Dips 1% as Stock Hovers Near Key Support at $0.28Value Area Low - Newser

Theriva Biologics (TOVX) Hovers Near Support After Modest DeclineCommunity Breakout Alerts - Newser

Theriva Biologics (TOVX) Delivers Q1 2026 Beat — EPS $-0.05 vs $-0.05 ExpectedShared Trade Ideas - Newser

Theriva Biologics (TOVX) Declines -9.35% Amid Market Weakness 2026-05-17Top Analyst Buy Signals - Newser

Theriva Biologics (TOVX) Falls -11.84% — Watching $0.27 Support 2026-05-15Diversification - Newser

BIOLASE Inc (BIOL) - Minichart

TradingKey - TradingKey

TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Theriva Biologics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart

Theriva Biologics Reports FDA Alignment on VCN-01 Phase 3 Trial Design for Metastatic Pancreatic Cancer and Q1 2026 Financial Results - Minichart

Theriva Biologics, Inc. 1Q 2026: Revenue $300K, Net income ($2.04M), EPS ($0.05) — 10-Q Summary - TradingView

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - The Manila Times

Theriva Biologics: Q1 Earnings Snapshot - marketscreener.com

Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan

Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan

Theriva moves pancreatic cancer drug toward Phase 3, cash into 2027 - Stock Titan

TOVX Forecast, Price Target & Analyst Ratings | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill

Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan

TOVX|Theriva Biologics Inc|Price:0.330|Chg%:-0.03 - TradingKey

Theriva Biologics (TOVX) price target decreased by 42.86% to 4.08 - MSN

Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo

Ähnlich wie TOVX